Cargando…
The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494625/ https://www.ncbi.nlm.nih.gov/pubmed/34617150 http://dx.doi.org/10.1007/s00134-021-06540-w |
| _version_ | 1784579352609947648 |
|---|---|
| author | Tatham, Kate C. Shankar-Hari, Manu Arabi, Yaseen M. |
| author_facet | Tatham, Kate C. Shankar-Hari, Manu Arabi, Yaseen M. |
| author_sort | Tatham, Kate C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8494625 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84946252021-10-08 The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19? Tatham, Kate C. Shankar-Hari, Manu Arabi, Yaseen M. Intensive Care Med Editorial Springer Berlin Heidelberg 2021-10-07 2021 /pmc/articles/PMC8494625/ /pubmed/34617150 http://dx.doi.org/10.1007/s00134-021-06540-w Text en © Springer-Verlag GmbH Germany, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Editorial Tatham, Kate C. Shankar-Hari, Manu Arabi, Yaseen M. The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19? |
| title | The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19? |
| title_full | The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19? |
| title_fullStr | The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19? |
| title_full_unstemmed | The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19? |
| title_short | The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19? |
| title_sort | remdacta trial: do interleukin receptor antagonists provide additional benefit in covid-19? |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494625/ https://www.ncbi.nlm.nih.gov/pubmed/34617150 http://dx.doi.org/10.1007/s00134-021-06540-w |
| work_keys_str_mv | AT tathamkatec theremdactatrialdointerleukinreceptorantagonistsprovideadditionalbenefitincovid19 AT shankarharimanu theremdactatrialdointerleukinreceptorantagonistsprovideadditionalbenefitincovid19 AT arabiyaseenm theremdactatrialdointerleukinreceptorantagonistsprovideadditionalbenefitincovid19 AT tathamkatec remdactatrialdointerleukinreceptorantagonistsprovideadditionalbenefitincovid19 AT shankarharimanu remdactatrialdointerleukinreceptorantagonistsprovideadditionalbenefitincovid19 AT arabiyaseenm remdactatrialdointerleukinreceptorantagonistsprovideadditionalbenefitincovid19 |